Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 31Gynecologic 5Gastrointestinal 4Thoracic 3Genitourinary 3Head & Neck 2Other solid neoplasm 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

Carboplatin 88pembrolizumab 77Pemetrexed 65Cisplatin 56Paclitaxel 33Docetaxel 31durvalumab 28atezolizumab 28Nivolumab 28Specimen Handling 25Magnetic Resonance Spectroscopy 20Gemcitabine 19osimertinib 18130-nm albumin-bound paclitaxel 18Etoposide 17Radiotherapy 14Cetuximab 14Platinum 12Taxes 11Immunoglobulin G 101,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Ipilimumab 9Disulfides 9Bevacizumab 9amivantamab 8Topotecan 8fludarabine 7Ramucirumab 7Radiosurgery 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Fulvestrant × Thoracic × 30 days × Clear all
NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeOne Medicines

Phase 1 Active not recruiting
103 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06120283 2026-05-27

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
399 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07540572 2026-05-20

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

IDEAYA Biosciences

Phase 1/2 Recruiting
160 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡